ClinicalTrials.gg
CompletedNCT03311282Step-UpUpdated Oct 18, 2017

New Chicco Bottles Study

An interventional study of infants bottles and Infants Bottles in Feeding Behavior, sponsored by Sprim Advanced Life Sciences. Completed. Open to participants aged 1 Day to 10 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-18.

Sponsored by Sprim Advanced Life Sciences · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Jun 2014, registered Oct 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
1 Day to 10 Months
Sex
All
01

Study summary

Breastfeeding is recommended as the ideal form of nutrition for newborns and infants at least for the first 6 months of life by several Institutions such as the American Academy of Pediatrics (AAP) and the World Health Organization (WHO).

When breastfeeding is not possible or not desirable, bottle-feeding, in most cases using a proper infant formula, is the right alternative.

Both facial and cranial growth and development rely on genetic and external stimuli; the latter are provided also by activities of sucking, swallowing and chewing. Considering this, it is important to show the differences between the activities of the muscles (masseter, temporalis and buccinator) in charge of sucking during breastfeeding or bottle-feeding.

The activities of the muscles were evaluated through SLI, which consists of the assessment of muscle functioning by analyzing the displacement of a defined point on a given muscle. This displacement is tracked over time with respect to a fixed frame of reference, thus providing velocity data (i.e. speed) for a certain point on the muscle during muscle contraction. The use of SLI allowed us to determine the activity of oral muscles on the different types of feeding and to compare their strength and activity.

Principal aims of the present study was to assess the activity of the orbicularis oris muscle (OM) and of the masseter, temporalis and buccinator muscles (MM, TM and BM) (i.e. the muscles in charge of sucking during breastfeeding) during breastfeeding and bottle-feeding by means of SLI. The new Chicco feeding bottles Natural Feeling (Natural Fit) 0m+, 4m+ and 6m+ were used according to the age of the infants.

Moreover, the following parameters were evaluated comparing breastfeeding and bottle-feeding: feeding efficiency (measured as ml/minute milk intake considering an interval of 15 minutes) and oxygen saturation during feeding (assessed by pulse oximetry). Moreover colic-like symptoms over 9 weeks (0 to 4 weeks infant only) were evaluated through the Infant Colic Scale.

Read the detailed description

By means of SLI technique positive preliminary results as regards comparison between bottle feeding with the New Chicco Bottles and breastfeeding were reached; these results allow to conclude that, considering feeding features related to growth and development, bottle-feeding with the new Chicco bottles can biomimic the suction muscular dynamics of breastfeeding.

A proper growth is confirmed in bottle-feeding groups also by means of evaluations of growth parameters, and it is guaranteed by the evaluation of the oxygen saturation during feeding, that is similar among groups.

As regards evaluation of colic underlying causes in infants ages 0-4 weeks it is possible to state that no differences were found in bottle-fed and breastfed infants: given the lack of differences between the groups, whichever the underlying reason for colic symptomatology could exist, it is possible to infer that using one or the other kind of feeding does not have an impact on symptoms, or had a minor one.

As regards the product satisfaction evaluated comparing the bottle-fed groups positive results were reached in all the evaluation, at V2, Week 5 and Week 9, reaching always a mean score > 8.

Notwithstanding the positive results above outlined a confirmatory study, envisaging a bigger sample size, it is advisable, to confirm and emphasize the results already achieved.

For each trial participant the adverse events/serious adverse events occurrences and a brief clinical examination were assessed during Visits. No special or unusual features of the safety evaluations were found.

02

Conditions studied

  • Feeding Behavior

Keywords

  • breastfeeding
  • infants
  • squeezing
  • breathing
03

In context

Feeding Behavior

985 studies on the registry are indexed under Feeding Behavior; 178 are open to participants now.

This study's enrollment of 61 is below the median of 77 across 700 interventional studies indexed under Feeding Behavior.

Browse Feeding Behavior studies →

Lead sponsor

Sprim Advanced Life Sciences is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 10 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female infants aged 0 to 10 months according to the following:

Group 1: age 0-4 weeks (+/- 7 days) Group 2: age 4 months (+/- 10 days) Group 3: age 6-10 months (+/- 10 days) Group 4: age 0-4 weeks (+/- 7 days) Group 5: age 4 months (+/- 10 days) Group 6: age 6-10 months (+/- 10 days)

  • Infants exclusively or prevalently breast- or bottle-fed
  • Full-term infants (≥ 37 weeks of gestation) with APGAR at birth (5 min) ≥ 8 by parent report
  • Birth weight ≥ 2.5 kg by parent report
  • Capability of the parents / legal guardians, according to Investigator's opinion, to fully comprehend the nature of the study
  • Parents / legal guardians' written consent to the study and willingness to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Birth defect, injury or health condition that interferes with sucking, feeding or breathing
  • Any medical condition or disease that may affect subject safety or confound study results, including cardiac or neurological defects
  • Infants born from twin or multiple pregnancy
  • Any other condition that, in the Investigator's opinion, may preclude the subject's ability to safely complete the trial
  • Parents / legal guardians uncooperative and/or non-compliant according to Investigator's opinion
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Feeding Bottle 0m+

    10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle. 0-4 months, 250 ml, 2 angled teats: newborn (also referred to as low flow) and infant (also referred to as medium flow), for infants aged 0-4 weeks (+/- 7 days) / over 9 weeks of participation.

    Device: infants bottles

  • Experimental
    Feeding Bottle 4m+

    10 infants aged 4 months (+/- 10 days): 4-6 m bottle. 4-6 months, 250 ml, non-angled teat), for infants aged 4 months (+/- 10 days) / over 9 weeks of participation.

    Device: Infants Bottles

  • Experimental
    Feeding Bottle 6m+

    10 infants aged 6-10 months (+/- 10 days): 6m+ bottle. 6 months and over, 250 ml, longer teat) for infants aged form 6 to 10 months (+/- 10 days) / over 9 weeks of participation.

    Device: Infants Bottles

  • No intervention
    exclusively or prevalently breast-fed infants 0m+

    10 infants aged 0-4 weeks (+/- 7 days)

  • No intervention
    exclusively or prevalently breast-fed infants 4m+

    10 infants aged 4 months (+/- 10 days)

  • No intervention
    exclusively or prevalently breast-fed infants 6m+

    10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)

Interventions

  • Deviceinfants bottles

    * angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position; * extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion * flexors at the base to enhance elasticity and flexibility of the teat

    Also known as: Natural Feeling/Natural Fit 0-4m:

  • DeviceInfants Bottles

    * large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion * non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck. * flexors at the base to enhance elasticity and flexibility of the teat

    Also known as: Natural Feeling/Natural Fit 4-6m:

  • DeviceInfants Bottles

    * teat with less rounded base to guarantee tighter lip support, which helps the "sucking" motion. * flexors at the base to enhance elasticity and flexibility of the teat

    Also known as: Natural Feeling/Natural Fit 6m+:

06

What researchers measure

Primary outcomes

  1. Mean Velocity orbicularis oris (OM) Muscle by means of SLI

    To assess the orbicularis oris muscle (OM) and the perioral muscles (masseter, temporalis and buccinator muscles - MM, TM and BM) activity during breast- or bottle-feeding through SLI of the face during a single feeding session considering 3 treatment groups + 3 comparison groups: Treatment groups: bottle-fed infants * Group 1: age 0-4 weeks (+/- 7 days): 0-4 m bottle * Group 2: age 4 months (+/- 10 days): 4-6 m bottle * Group 3: age 6-10 months (+/- 10 days): 6m+ bottle Control groups: exclusively or prevalently breast-fed infants * Group 4: age 0-4 weeks (+/- 7 days) * Group 5: age 4 months (+/- 10 days) * Group 6: age 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)

    Time frame: Week 2

  2. Mean Velocity masseter MM Muscle by means of SLI

    To assess the orbicularis oris muscle (OM) and the perioral muscles (masseter, temporalis and buccinator muscles - MM, TM and BM) activity during breast- or bottle-feeding through SLI of the face during a single feeding session considering 3 treatment groups + 3 comparison groups: Treatment groups: bottle-fed infants * Group 1: age 0-4 weeks (+/- 7 days): 0-4 m bottle * Group 2: age 4 months (+/- 10 days): 4-6 m bottle * Group 3: age 6-10 months (+/- 10 days): 6m+ bottle Control groups: exclusively or prevalently breast-fed infants * Group 4: age 0-4 weeks (+/- 7 days) * Group 5: age 4 months (+/- 10 days) * Group 6: age 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)

    Time frame: week 2

  3. Mean Velocity Temporalis Muscle by means of SLI

    To assess the orbicularis oris muscle (OM) and the perioral muscles (masseter, temporalis and buccinator muscles - MM, TM and BM) activity during breast- or bottle-feeding through SLI of the face during a single feeding session considering 3 treatment groups + 3 comparison groups: Treatment groups: bottle-fed infants * Group 1: age 0-4 weeks (+/- 7 days): 0-4 m bottle * Group 2: age 4 months (+/- 10 days): 4-6 m bottle * Group 3: age 6-10 months (+/- 10 days): 6m+ bottle Control groups: exclusively or prevalently breast-fed infants * Group 4: age 0-4 weeks (+/- 7 days) * Group 5: age 4 months (+/- 10 days) * Group 6: age 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)

    Time frame: week 2

  4. Mean Velocity Buccinator Muscle by means of SLI

    To assess the orbicularis oris muscle (OM) and the perioral muscles (masseter, temporalis and buccinator muscles - MM, TM and BM) activity during breast- or bottle-feeding through SLI of the face during a single feeding session considering 3 treatment groups + 3 comparison groups: Treatment groups: bottle-fed infants * Group 1: age 0-4 weeks (+/- 7 days): 0-4 m bottle * Group 2: age 4 months (+/- 10 days): 4-6 m bottle * Group 3: age 6-10 months (+/- 10 days): 6m+ bottle Control groups: exclusively or prevalently breast-fed infants * Group 4: age 0-4 weeks (+/- 7 days) * Group 5: age 4 months (+/- 10 days) * Group 6: age 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)

    Time frame: week 2

Secondary outcomes

  1. ml/minute milk intake during an interval of 15 minutes

    To evaluate feeding efficiency (ml/minute milk intake for 15 minutes) during a single feeding session of breast- or bottle-feeding considering each group; week 2;

    Time frame: week 2

  2. oxygen saturation

    To evaluate oxygen saturation through pulse oximetry during a single feeding session of breast- or bottle-feeding considering 3 treatment groups + 3 comparison groups (1, 2, 3, 4, 5, 6); this evaluation was be done at week 2;

    Time frame: week 2

  3. infant colic scale

    To evaluate colic-like symptoms over 9 weeks considering breast- or bottle-feeding groups in 0 to 4 weeks infants only (groups 1 and 4), through the validated Infant Colic Scale at week 5. The following items were considered: * Cow's milk/soy protein allergy intolerance: Max score 12 Min score 2 * Immature gastrointestinal system Max score 24 Min score 4 * Immature central nervous system Max score 48 Min score 8 * Difficult infant temperament Max score 24 Min score 4 * Parent infant interaction/Problem infant Max score 24 Min score 4 * Total score Max score 132 Min score 22 The difference between the study groups were evaluated. The scale was used to evaluate a possible difference between bottle- and breastfed infants, there's no "better" or "worse" outcome. Subscales are summed to compute a total score.

    Time frame: week 5

  4. infant colic scale

    To evaluate colic-like symptoms over 9 weeks considering breast- or bottle-feeding groups in 0 to 4 weeks infants only (groups 1 and 4), through the validated Infant Colic Scale at week 9. The following items were considered: * Cow's milk/soy protein allergy intolerance: Max score 12 Min score 2 * Immature gastrointestinal system Max score 24 Min score 4 * Immature central nervous system Max score 48 Min score 8 * Difficult infant temperament Max score 24 Min score 4 * Parent infant interaction/Problem infant Max score 24 Min score 4 * Total score Max score 132 Min score 22 The difference between the study groups were evaluated. The scale was used to evaluate a possible difference between bottle- and breastfed infants, there's no "better" or "worse" outcome. Subscales are summed to compute a total score.

    Time frame: week9

  5. overall product satisfaction (10 points likert scales)

    Overall product satisfaction at week 2. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10.

    Time frame: week 2

  6. overall product satisfaction (10 points likert scales)

    Overall product satisfaction at week 5. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10

    Time frame: week 5

  7. overall product satisfaction (10 points Likert scales)

    Overall product satisfaction at week 9. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10

    Time frame: week 9

  8. Ability of infant to latch onto bottle (10 points Likert scales)

    Ability of infant to latch onto bottle at week 2. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10

    Time frame: week 2

  9. Ability of infant to latch onto bottle (10 points Likert scales)

    Ability of infant to latch onto bottle at week 5

    Time frame: week 5

  10. Ability of infant to latch onto bottle (10 points Likert scales)

    Ability of infant to latch onto bottle at week 9. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10

    Time frame: week 9

  11. Infant comfort (10 points Likert scales)

    Infant comfort during feeding at week 2

    Time frame: week 2

  12. Infant comfort (10 points Likert scales)

    Infant comfort during feeding at week 5. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10

    Time frame: week 5

  13. Infant comfort (10 points Likert scales)

    Infant comfort during feeding at week 9. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10

    Time frame: week 9

  14. Ease of use by infant (10 points Likert scales)

    Ease of use by infant at week 2. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10

    Time frame: week 2

  15. Immediate acceptance by the infant (10 points Likert scales)

    Immediate acceptance by the infant at week 2. It is assessed on 0 to 10 points Likert scale; minimum value is 0, maximum is 10, corresponding to minimum and maximum satisfaction. The better outcome corresponds to a score equal to 10

    Time frame: week 2

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Oct 2014, 4 months.

Of 503 non-industry interventional studies with no phase under Feeding Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's 4 months is below that.

Counting every sponsor, half of 515 studies reached it within 14 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2017
First posted
Oct 17, 2017
StartActual
Jun 12, 2014
Primary completionActual
Oct 25, 2014
CompletionActual
Jan 5, 2015
Last update
Oct 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03311282
Lead sponsor
Sprim Advanced Life Sciences
Collaborators
Artsana S.p.a.
Responsible party
Sponsor
First posted
Oct 17, 2017
Start date
Jun 12, 2014
Primary completion
Oct 25, 2014
Completion
Jan 5, 2015
Last update
Oct 18, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion